FDA Places ASC618, Gene Therapy for Hemophilia A, on Fast Track
The U.S. Food and Drug Administration (FDA) has given fast track designation to ASC618, an investigational one-time gene therapy for hemophilia A in the pipeline of ASC Therapeutics. Fast track status works to speed the development and regulatory review of treatments for serious disorders that show a potential to fill an unmet need. The Committee for Orphan Medicinal Products … Read more